Early blood changes and treatment-related leukemia risk after ovarian cancer
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer
['FUNDING_R01'] · UNIVERSITY OF WASHINGTON · NIH-11324965
This project follows ovarian cancer survivors to look for early blood cell changes that can lead to treatment-related leukemia.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11324965 on ClinicalTrials.gov |
What this research studies
If you survived ovarian cancer, researchers plan to enroll about 2,000 survivors and collect blood samples and treatment histories. They will use genetic sequencing of blood cells to look for clonal hematopoiesis and mutations such as BRCA1/BRCA2 and TP53 that may grow after chemo or long-term PARP inhibitor use. The team will link those findings to each person’s chemotherapy and maintenance therapy exposure and follow participants over time to see who develops therapy-related myeloid neoplasms. The goal is to identify patterns and timing of risk that could guide safer treatment choices or early prevention.
Who could benefit from this research
Good fit: Ideal candidates are ovarian cancer survivors who have received chemotherapy and/or long-term PARP inhibitor maintenance, including those with known BRCA1/BRCA2 mutations.
Not a fit: People without a history of ovarian cancer or those who already have a diagnosed blood cancer are unlikely to benefit from this project’s prevention-focused work.
Why it matters
Potential benefit: If successful, this work could help identify people at high risk for treatment-related leukemia earlier and guide safer therapy or early prevention steps.
How similar studies have performed: Prior research in other cancer survivor groups has shown that clonal hematopoiesis can predict therapy-related blood cancers, but applying this approach specifically to ovarian cancer and long PARP use is newer.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SWISHER, ELIZABETH MARY — UNIVERSITY OF WASHINGTON
- Study coordinator: SWISHER, ELIZABETH MARY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.